WIRB-Copernicus Group (WCG) and Prostate Cancer Clinical Trials Consortium (PCCTC) announced their new partnership to enhance the quality and efficiency of the Consortium’s research review process.

PCCTC joins the nation’s most prominent cancer research institutions in relying on WCG for the review of its cancer research protocols and related study documents. WCG Oncology™, WCG’s cancer-focused division, is comprised of experts who specialize in oncological sub-specialties and advise WCG’s three cancer-focused institutional review board (IRB) panels on the science behind cutting-edge therapies. With a deep understanding of the underlying science and clinical aspects of associated therapies, WCG Oncology’s IRB panels provide a highly informed, thorough review of new approaches and proposed research in oncology.

News coverage of this announcement is highlighted below:

Publication: Applied Clinical Trials
To read this article, please click here

Publication: Applied Clinical Trials – Oncology Special Edition
To read this article, please click here

Publication: BioPortfolio
To read this article, please click here

Publication: BioSpace
To read this article, please click here

Publication: CenterWatch News Online
To read this article, please click here

Publication: CenterWatch Weekly

Publication: Clinical Informatics News
To read this article, please click here

Publication: PharmaVOICE.com
To read this article, please click here

Print Friendly